# COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Source: https://onco.cc/trials/nct04068610/  
OnCo record `nct04068610` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Durvalumab, Oleclumab, FOLFOX in colorectal cancer, run by MedImmune LLC, active and no longer recruiting.

## Summary

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC is a phase 1/2 interventional study registered as NCT04068610 by MedImmune LLC, with 61 participants enrolled, started 2019-09-13 and due to reach its primary completion in 2022-10-10. Interventions recorded: Durvalumab, Oleclumab, FOLFOX, Bevacizumab. Conditions listed: Metastatic Microsatellite-stable Colorectal Cancer. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: COLUMBIA-1
- Tags: ctgov-ingest
- Registry id: NCT04068610
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
- Sponsor: MedImmune LLC
- Enrolled: 61
- Outcomes: Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2: Part 2 (C1): FOLFOX + Bevacizumab 46.2% vs Part 2 (E1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab 61.5%; Overall Survival (OS) Per RECIST v1.1 in Part 1: Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab 30.1 months; Progression-Free Survival (PFS) Per RECIST v1.1 in Part 1: Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab 9.5 months

## Sources

- ClinicalTrials.gov NCT04068610: https://clinicaltrials.gov/study/NCT04068610

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Oleclumab](https://onco.cc/drugs/oleclumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer](https://onco.cc/key-papers/paper-nct04068610-br-j-cancer-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct04068610.json